After clinical trials demonstrated its safety and efficacy, the US Food and Drug Administration approved a new option for adult patients with tardive dyskinesia.
The FDA is requiring boxed warnings for opioid analgesics and prescription opioid cough products related to combined use of certain opioids with benzodiazepines.
